No Data
No Data
Analysts Offer Insights on Healthcare Companies: Tourmaline Bio (TRML), Amicus (FOLD) and Kura Oncology (KURA)
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $15
Buy Rating Affirmed for Tourmaline Bio Amid Promising Clinical Trials and Strong Market Potential
Tourmaline Bio | 10-Q: Q2 2024 Earnings Report
Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock
Talaris Therapeutics GAAP EPS of -$0.68